FirephoxRising writes "Traditionally ultrasound has seen limited use in cancer treatment due to clarity and resolution issues. But researchers at the UNC School of Medicine have overcome this limitation by combining ultrasound with a contrast agent composed of tiny bubbles that pair with an antibody that many cancer cells produce at higher levels than do normal cells. 'The SFRP2-moleculary targeted contrast agent showed specific visualization of the tumor vasculature,' said Klauber-DeMore. 'In contrast, there was no visualization of normal blood vessels. This suggests that the contrast agent may help distinguish malignant from benign masses found on imaging.'"